Novel Chitosan-Functionalized Spherical Nanosilica Matrix As an Oral Sustained Drug Delivery System for Poorly Water-Soluble Drug Carvedilol
Source abstract
Abstract
A novel spherical nanosilica matrix (SNM) together with chitosan (CTS) encapsulated SNM (CTS-SNM) was developed in order to investigate the feasibility of using chitosan to regulate drug release rate from porous silica and obtain an oral sustained drug delivery system. To achieve this goal, we synthesized a spherical nanosilica matrix (SNM) and incorporated chitosan chains on the SNM surface. Solvent evaporation method was adopted to load the model drug carvedilol into SNM and CTS-SNM. The physicochemical properties of the drug carriers and drug-loaded composites were systematically studied using scanning electron microscopy (SEM), transmission electron microscopy (TEM), nitrogen adsorption, X-ray diffraction (XRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). The structural changes in CTS-SNM in simulated gastrointestinal fluid as well as the relationships between swelling effect of chitosan and in vitro drug release behaviors were investigated. Pharmacokinetic and bioavailability aspects were also discussed. The results showed that the powerful dispersing effect of SNM and the blocking action due to the swelling of chitosan were the two main factors contributing to the sustained drug release behavior. The swelling effect of chitosan in an acidic environment together with the shrinking effect in a relatively alkaline environment allowed regulation of drug release behavior in simulated gastrointestinal fluid. An in vivo study showed that the bioavailability of CAR was improved 182% compared with that of the commercial capsule when SNM was used as the drug carrier. As for CAR-CTS-SNM, the T(max) of CAR was delayed by about 3.4 h and the bioavailability was slightly increased in comparison with the commercial capsule. We believe that SNM and CTS-SNM developed in this study will help increase the use of polymers and inorganic materials in pharmaceutical applications and stimulate the design of oral drug delivery systems for immediate or sustained release of poorly water-soluble drugs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Mesoporous Materials and Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Shenyang Pharmaceutical University, P.O. Box 32, Liaoning Province, Shenyang 110016, P.R. China.
Key laboratory of Pharmaceutical Biotechnology, School of Life Science and Bio-pharmaceutics, Shenyang Pharmaceutical University, Liaoning Province, Shenyang 110016, P.R. China
References (36)
Show source-provided references
1. Hughes G. A. · Nanomed. Nanotechnol. Biol. Med. · 2005 · 1 · 2210.1016/j.nano.2004.11.009 ↗
2. Vallet-Regí M. · Angew. Chem., Int. Ed. · 2007 · 46 · 754810.1002/anie.200604488 ↗
3. Parveen S. · Nanomed. Nanotechnol. Biol. Med. · 2012 · 8 · 14710.1016/j.nano.2011.05.016 ↗
4. Slowing I. I. · Adv. Drug Delivery Rev. · 2008 · 60 · 127810.1016/j.addr.2008.03.012 ↗
5. Anglin E. J. · Adv. Drug Delivery Rev. · 2008 · 60 · 126610.1016/j.addr.2008.03.017 ↗
6. Wang S. · Microporous Mesoporous Mater. · 2009 · 117 · 110.1016/j.micromeso.2008.07.002 ↗
7. Zhang Y. · Eur. J. Pharm. Biopharm. · 2010 · 76 · 1710.1016/j.ejpb.2010.05.010 ↗
8. Du X. · Nanoscale · 2011 · 3 · 398410.1039/c1nr10660k ↗
9. Hu Y. · Eur. J. Pharm. Biopharm. · 2011 · 79 · 54410.1016/j.ejpb.2011.07.001 ↗
10. Zhang Y. · Int. J. Pharm. · 2011 · 410 · 11810.1016/j.ijpharm.2010.07.040 ↗
11. Hu Y. · J. Colloid Interface Sci. · 2011 · 363 · 41010.1016/j.jcis.2011.07.022 ↗
12. Zhang Y. · Mol. Pharm. · 2012 · 9 · 50510.1021/mp200287c ↗
13. Mout R. · Chem. Soc. Rev. · 2012 · 41 · 253910.1039/c2cs15294k ↗
14. Manzano M. · J. Mater. Chem. · 2010 · 20 · 559310.1039/b922651f ↗
15. Arruebo M. · Wires Nanomed. Nanobiol. · 2012 · 4 · 1610.1002/wnan.132 ↗
16. Ganta S. · J. Controlled Release · 2008 · 126 · 18710.1016/j.jconrel.2007.12.017 ↗
17. Rosenholm J. M. · Nanoscale · 2010 · 2 · 187010.1039/c0nr00156b ↗
18. Kesisoglou F. · Adv. Drug Delivery Rev. · 2007 · 59 · 63110.1016/j.addr.2007.05.003 ↗
19. Lou X. · J. Controlled Release · 2011 · 152 · e6510.1016/j.jconrel.2011.08.126 ↗
20. Jain T. K. · J. Am. Chem. Soc. · 1998 · 120 · 1109210.1021/ja973849x ↗
21. Zou H. · Chem. Rev. · 2008 · 108 · 389310.1021/cr068035q ↗
22. Barbé C. · Adv. Mater. (Weinheim, Ger.) · 2004 · 16 · 195910.1002/adma.200400771 ↗
23. Uhrich K. E. · Chem. Rev. · 1999 · 99 · 318110.1021/cr940351u ↗
24. Pillai O. · Curr. Opin. Chem Biol. · 2001 · 5 · 44710.1016/S1367-5931(00)00227-1 ↗
25. Du X. · Langmuir · 2010 · 26 · 1005710.1021/la100196j ↗
26. Boissière C. · Chem. Mater. · 2003 · 15 · 50910.1021/cm0211195 ↗
27. Lvov Y. · Langmuir · 1997 · 13 · 619510.1021/la970517x ↗
28. López F. · J. Therm. Anal. Calorim. · 2008 · 91 · 63310.1007/s10973-007-8321-3 ↗
29. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
30. Everett D. · Pure Appl. Chem. · 1985 · 57 · 60310.1351/pac198557040603 ↗
31. Pokharkar V. B. · Powder Technol. · 2006 · 167 · 2010.1016/j.powtec.2006.05.012 ↗
32. Shamblin S. L. · Pharm. Res. · 1998 · 15 · 182810.1023/A:1011997721086 ↗
33. Brook, C. S.; Chen, W.; Dell’Orco, P. C.; Katrincic, L. M.; Louvet, A. M.; Oh, C. K.; Spoors, P. G.; Werner, C.Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment. U.S. Patent 7 268 156, Sept 11, 2007.
34. Planinšek O. · Int. J. Pharm. · 2011 · 406 · 4110.1016/j.ijpharm.2010.12.035 ↗
35. Rohindra D. R. · J. Nat. Appl. Sci. · 2004 · 22 · 32
36. Fonarow G. C. · Expert Opin. Pharmacother. · 2006 · 7 · 253310.1517/14656566.7.18.2533 ↗